The domestic logistics platform will expand to four centers by
As part of the Business Continuity Plan (BCP), maintaining a stable supply of pharmaceuticals even during pandemic of infectious disease or natural disasters such as earthquakes, storms, and flooding is one of the most important missions of a pharmaceutical company. Moreover, in
In view of the situation mentioned above, Astellas has decided to increase the number of domestic logistics centers from the current three centers to four for reducing the risk in distribution, thereby further strengthen its system for ensuring a stable supply of pharmaceuticals. Astellas believes that ensuring an even more robust system for a stable product supply cannot be developed by Astellas alone and considers the cooperation of the stakeholders involved with logistics of pharmaceuticals, including other pharmaceutical companies, as well as the standardization of processes, to be of crucial importance. Astellas aims to establish, at logistics centers in Kyushu as well as in western and eastern
The creation of a stable and efficient logistics platform will enable Astellas to fulfill its mission of maintaining a stable supply of pharmaceutical products and ensuring their quality at all times. It will also give a sense of security to patients and medical institutions.
Astellas has already reflected the impact from this decision in its financial forecast of the current fiscal year ending
About Astellas
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contact:
Tel: +81-3-3244-3201
Fax: +81-3-5201-7473
(C) 2020 Electronic News Publishing, source